Clinical trials
catalyst calendar across sponsors →Studies where CRBU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 observational
Held by 11 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, MAVERICK CAPITAL LTD, Qube Research & Technologies Ltd, MARSHALL WACE, LLP, +6 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Follow-up StudyNCT05332054observationalIncidence of targeted NSAEs | — | Enrolling by invitation | Biological: Caribou-sponsored investigational therapy | Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia | 150 | Dec 2041 | ≤ 5,612 d | 2026-03-12 |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaNCT05722418(Part A) Number of patients with dose limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Recruiting | Biological: CB-011 | Relapsed/Refractory Multiple Myeloma | 50 | Dec 2027 | ≤ 498 d | 2025-09-25 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)NCT06752876Incidence of critical safety events (CSEs) ≤ 28days after CB-010 infusionNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs | Drug: CB-010 | Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis | 0 | Apr 2029 | ≤ 984 d | 2025-09-19 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)NCT04637763Primary outcome measures number of patients with dose-limiting toxicities (Part A).Non-randomized · Open-label · Treatment | Phase 1 | Unknown status | Genetic: CB-010 · Drug: Cyclophosphamide, Fludarabine | Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma | 72 | Aug 2025 | — | 2025-03-24 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT06128044(Part A) Number of patients with dose limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision - Pipeline Reprioritization | Drug: CB-012 | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12 | 2025-05-30actual | — | 2025-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19